| 초록 |
Many anti-tumor drug strategies aim to facilitate and mediate specific interactions between individual cells and engineered cytotoxic drug carriers. Various examples take advantage of antigen/monoclonal antibody or ligand/receptor pair interaction, where one half of the pair is incorporated into the drug carrier to facilitate targeting to the other member of the pair on the tumor surface. Unfortunately, these approaches have achieved limited success, most likely because solid tumors display a broad heterogeneity of cell types and cell surface marker profiles as well as dynamic antigens or receptors expression on cell surface. To overcome this requires a more general targeting method. Our approach is through a re-engineering of polymeric micelles where the natural acidity of tumors is exploited to facilitate active entry into the tumor cells. This approach alleviates the need for cell-specific antibodies or targeting ligands, thereby providing a general strategy for tumor targeting. |
